文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

亚组不成比例分析探索全球个例安全报告数据库对日本常见药物基因组风险变异的敏感性

The Use of Subgroup Disproportionality Analyses to Explore the Sensitivity of a Global Database of Individual Case Safety Reports to Known Pharmacogenomic Risk Variants Common in Japan.
PubMed 文献 · Drug Saf · 2021-04-10

研究基于VigiBase全球个例安全报告数据库(2020年1月5日冻结版),采用亚组不成比例分析比较日本与世界其他地区在伊立替康、伏立康唑、艾司西酞普兰和氯吡格雷相关报告中的差异。结果显示,日本亚组对特定不良反应的过度报告模式与已知药物基因组风险变异一致, bootstrap HMP分析支持该模式(伊立替康p=0.004,其他药物p<0.001),且可观察到剂量调整和治疗药物监测的影响。

要点

  • 全球ICSR数据库可反映药物基因组差异导致的不良反应报告地区差异。
  • 日本亚组中伊立替康、伏立康唑、艾司西酞普兰和氯吡格雷的特定ADR过度报告与已知基因变异一致。
  • 区域分析有助于评估当地风险最小化措施(如剂量调整、TDM)的实施效果。

核心结论

  • 药物基因组差异可能导致全球ICSR数据库中不同国家间ADR报告差异。
  • 全球数据库的区域分析可评估当地风险最小化措施效果,并促进基于种族的个体化安全用药。

研究设计与样本

  • 数据源为VigiBase全球个例安全报告数据库,纳入2020年1月5日冻结版本的所有报告。
  • 采用亚组不成比例分析比较日本与世界其他地区(RoW)两个亚组。
  • 选择UGT1A1代谢的伊立替康和CYP2C19代谢的伏立康唑、艾司西酞普兰、氯吡格雷相关报告进行比较。
  • 使用IC delta(对数尺度的稳健收缩观察/预期比值)量化亚组间差异,并计算调和平均p值(HMP)。
  • 对信息充分的ICSR计算每日药物剂量,比较日本与RoW的剂量分布并与区域批准剂量关联。

主要发现

  • 特定ADR的过度报告模式预测得到bootstrap HMP分析确认:伊立替康p=0.004,伏立康唑、艾司西酞普兰和氯吡格雷各p<0.001。
  • 与代谢途径不同的类似药物比较,进一步支持上述模式。
  • 全球数据库内可观察到主动监管措施(如推荐剂量和治疗药物监测)的影响。
  • 伊立替康和艾司西酞普兰有证据显示使用日本标签推荐的较低剂量。
  • 伏立康唑有证据显示使用TDM,表现为药物浓度监测相关术语过度报告而肝毒性 under-reporting。

临床怎么用

  • 在临床药学实践中,可参考全球ICSR数据库的区域亚组分析结果,识别因药物基因组差异导致的高风险药物和ADR。
  • 针对日本常见基因变异(如UGT1A1、CYP2C19),应关注伊立替康、伏立康唑、艾司西酞普兰和氯吡格雷的个体化剂量调整和TDM。
  • 利用区域分析评估本地风险最小化措施(如剂量推荐、TDM)的实施效果,促进安全用药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Genetic variations of enzymes that affect the pharmacokinetics and hence effects of medications differ between ethnicities, resulting in variation in the risk of adverse drug reactions (ADR) between different populations. Previous work has demonstrated that risk-group considerations can be incorporated into approaches of statistical signal detection. It is unknown whether databases of individual case safety reports (ICSRs) are sensitive to pharmacogenomic differences between populations. OBJECTIVE: The aim of this study was to explore the sensitivity of a global database of ICSRs to known pharmacogenomic risk variants common in Japan. METHODS: The data source was VigiBase, the global database of ICSRs, including all reports entered in the version frozen on 5 January 2020. Subgroup disproportionality analysis was used to compare ICSRs of two subgroups, Japan and rest of world (RoW). Reports for UGT1A1-metabolized irinotecan and the CYP2C19-metabolized drugs voriconazole, escitalopram and clopidogrel were selected for comparison between the subgroups based upon known genetic polymorphisms with high prevalence in Japan. Contrast between the subgroups was quantified by IC delta [Formula: see text]), a robust shrinkage observed-to-expected (OE) ratio on a log scale. Harmonic mean p values (HMP) were calculated for each drug to evaluate whether a list of pre-specified ADRs were collectively significantly over- (or under-)reported as hypothesized. Daily drug dosages were calculated for ICSRs with sufficient information, and dose distributions were compared between Japan and RoW and related to differences in regionally approved doses. RESULTS: The predictions of over-reporting patterns for specific ADRs were observed and confirmed in bootstrap HMP analyses (p = 0.004 for irinotecan and p < 0.001 for each of voriconazole, escitalopram and clopidogrel) and compared with similar drugs with different metabolic pathways. The impact of proactive regulatory action, such as recommended dosing and therapeutic drug monitoring (TDM), was also observable within the global database. For irinotecan and escitalopram, there was evidence of use of lower dosages as recommended in the Japanese labels; for voriconazole, there was evidence of use of TDM with an over-reporting of terms related to drug level measurements and an under-reporting of liver toxicity. CONCLUSIONS: Pharmaco-ethnic vulnerabilities caused by pharmacogenomic differences between populations may contribute to differences in ADR reporting between countries in a global database of ICSRs. Regional analyses within a global database can inform on the effectiveness of local risk minimization measures and should be leveraged to catalyse the conversion of real-world usage into safer use of drugs in ethnically tailored ways.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Wakao R, Lönnstedt IM, Aoki Y, et al. The Use of Subgroup Disproportionality Analyses to Explore the Sensitivity of a Global Database of Individual Case Safety Reports to Known Pharmacogenomic Risk Variants Common in Japan. Drug Saf. 2021. PMID: 33837924. doi:10.1007/s40264-021-01063-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。